Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VYXEOS vs MISOPROSTOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Daunorubicin and cytarabine are both antineoplastic agents. Daunorubicin intercalates with DNA, inhibits topoisomerase II, and generates free radicals leading to DNA damage and cell death. Cytarabine is a nucleoside analog that inhibits DNA polymerase by competing with cytidine triphosphate, incorporating into DNA and RNA, and causing chain termination.
Misoprostol is a synthetic prostaglandin E1 analog that induces uterine contractions and cervical ripening by binding to prostaglandin receptors, leading to increased intracellular calcium and myometrial contraction. It also inhibits gastric acid secretion by reducing parietal cell activity and protecting gastric mucosa via increased bicarbonate and mucus production.
FDA: Treatment of newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients aged 1 year and older.
Prevention and treatment of NSAID-induced gastric ulcers,Medical abortion (with mifepristone or methotrexate),Cervical ripening and induction of labor,Management of postpartum hemorrhage,Off-label: Missed abortion, intrauterine fetal death, incomplete abortion
Each unit contains 44 mg daunorubicin and 100 mg cytarabine. Adults: 1 unit/m² IV over 90 minutes on days 1, 3, and 5 for induction; up to 2 cycles. For consolidation: 1 unit/m² IV over 90 minutes on days 1 and 3; up to 2 cycles.
200 mcg orally four times daily (with meals and at bedtime) for prevention of NSAID-induced gastric ulcers; 800 mcg sublingually every 4 hours for up to 3 doses for labor induction; 25 mcg orally single dose for cervical ripening.
Daunorubicin: terminal half-life approximately 56 h; cytarabine: terminal half-life approximately 31 h. The prolonged half-lives reflect sustained release from liposomes, allowing continuous exposure.
2-3 hours for misoprostol acid (active metabolite); clinically, a short duration requires multiple daily dosing. In patients with renal impairment, half-life may be prolonged but not significantly clinically.
Daunorubicin is metabolized via aldo-keto reductases to daunorubicinol, which is active. Cytarabine is primarily metabolized by cytidine deaminase to inactive uracil arabinoside (ara-U).
Hepatic, primarily via de-esterification to misoprostol acid (active metabolite), which undergoes further oxidation and reduction; CYP450 minimal involvement; metabolites excreted renally.
Primarily hepatobiliary excretion; 70-80% of dose recovered in feces as metabolites, less than 10% in urine as unchanged liposomal daunorubicin and cytarabine.
Primarily renal excretion of metabolites; ~80-90% of a radiolabeled dose is excreted in urine within 24 hours, with the remainder in feces. Misoprostol acid (active metabolite) undergoes further beta-oxidation and reduction; <1% excreted unchanged.
Daunorubicin: approximately 60-70% bound to albumin and tissue proteins; cytarabine: approximately 15% bound to albumin.
80-89% bound to albumin (specifically to human serum albumin). Binding is saturable at high concentrations.
Daunorubicin: Vd approximately 0.5-1 L/kg, indicating extensive tissue distribution; cytarabine: Vd approximately 0.3-0.5 L/kg, distributed mainly in total body water.
Apparent Vd of misoprostol acid: approximately 0.3-0.5 L/kg. This indicates distribution primarily into extracellular fluid; low tissue binding.
Not applicable (IV only); oral bioavailability not established for liposomal formulation.
Oral: ~60% (rapid and extensive first-pass metabolism to misoprostol acid); Vaginal/buccal/sublingual: bioavailability is higher (~70-80%) due to partial avoidance of first-pass metabolism.
Contraindicated in severe renal impairment (Cr Cl < 30 m L/min). For Cr Cl 30-60 m L/min: reduce dose by 25%. Monitor renal function.
No dose adjustment required for GFR > 30 m L/min; for GFR 10-30 m L/min, consider reducing oral dose by 50% if GI adverse effects occur; for GFR < 10 m L/min, use with caution and monitor for toxicity.
Contraindicated in severe hepatic impairment (Child-Pugh C). For Child-Pugh B: reduce dose by 50%. For Child-Pugh A: no adjustment needed.
Child-Pugh A: No adjustment; Child-Pugh B: No data, use with caution; Child-Pugh C: Not studied, avoid use.
Safety and efficacy not established. No standard pediatric dosing. Use only in clinical trials.
Safety and efficacy not established for most indications; for congenital heart disease with NSAID-induced ulcer risk, limited data suggest 2-5 mcg/kg/dose orally four times daily (max 200 mcg/dose).
No specific dose adjustment based on age alone. Monitor renal and hepatic function; consider dose reduction in frail elderly patients due to increased toxicity risk.
Start at lower end of dosing range (e.g., 100 mcg orally four times daily) due to increased risk of diarrhea and hypotension; titrate slowly based on tolerance.
WARNING: DAUNORUBICIN IS A CARDIOTOXIC AGENT. DAUNORUBICIN CAN CAUSE MYELOSUPPRESSION AND SEVERE BLEEDING. VYXEOS IS A LIPOSOMAL FORMULATION; DO NOT SUBSTITUTE FOR OTHER DAUNORUBICIN OR CYTARABINE PRODUCTS.
Misoprostol is contraindicated in pregnant women for the prevention of NSAID-induced gastric ulcers because it can cause abortion. If used for induction of labor or abortion, careful patient selection and monitoring are required. It may cause uterine hyperstimulation, leading to fetal distress, uterine rupture, or maternal death.
Cardiotoxicity: Left ventricular dysfunction, especially with cumulative doses; monitor cardiac function.,Myelosuppression: Severe, can lead to fatal infections or bleeding.,Hemorrhage: Fatal hemorrhages reported.,Tumor lysis syndrome: Risk due to rapid lysis.,Hepatotoxicity: Elevations in bilirubin and transaminases.,Embryo-fetal toxicity: Can cause fetal harm; advise effective contraception.
Uterine hyperstimulation and rupture (especially with prior uterine surgery or grand multiparity),Fetal distress and meconium passage,Maternal hypotension and tachycardia,Gastrointestinal effects (diarrhea, abdominal pain),Avoid in pregnancy for peptic ulcer disease indication,Not to be used as a cervical ripener in patients with uterine scar or fetal distress
Hypersensitivity to daunorubicin, cytarabine, or any component of the formulation.,History of serious hypersensitivity reactions to any conventional daunorubicin or cytarabine product.
Pregnancy (for ulcer prevention; used intentionally for abortion/labor induction under specific protocols),Hypersensitivity to misoprostol or prostaglandins,History of cesarean section or major uterine surgery (relative for labor induction),Placenta previa or vasa previa,Active genital herpes or pelvic inflammatory disease (relative for abortion)
No specific food interactions reported. Avoid grapefruit and grapefruit juice due to potential CYP3A4 interaction with other components, although data are limited. Maintain adequate hydration to prevent tumor lysis syndrome.
No specific food interactions. Avoid magnesium-containing antacids as they may worsen diarrhea. Take with food to reduce gastrointestinal upset.
VYXEOS (daunorubicin and cytarabine liposome) is contraindicated in pregnancy. It is embryotoxic and fetotoxic in animals. First trimester: high risk of major malformations (neural tube, cardiac). Second/third trimester: risk of fetal growth restriction, preterm birth, and neonatal myelosuppression. Use effective contraception.
Misoprostol is a prostaglandin E1 analogue that stimulates uterine contractions and causes cervical ripening. It is contraindicated in pregnancy due to its abortifacient properties. First trimester exposure may cause uterine rupture, fetal death, or congenital anomalies (e.g., Möbius syndrome, limb defects). Second and third trimester use is limited to induction of labor or abortion; risks include uterine hyperstimulation, fetal distress, and meconium passage. Post-term effects: none specified.
Not recommended. It is unknown if excreted into human milk. M/P ratio not available. Advise to discontinue breastfeeding during treatment and for at least 1 month after last dose due to potential for serious adverse reactions in breastfed infants.
Misoprostol is excreted into breast milk in small amounts (M/P ratio 1.0-1.4). No adverse effects in nursing infants have been reported. However, caution is advised when used postpartum for hemorrhage due to potential diarrhea in the infant. Alternative agents may be preferred.
No established dosing guidelines in pregnancy. Avoid use; if therapy is necessary, dose adjustments based on pharmacokinetic changes are not defined. Use only if potential benefit justifies risk to fetus.
Pharmacokinetics in pregnancy: No significant changes in absorption or clearance require dose adjustment. However, dosing regimens differ by indication (e.g., 200-600 mcg for labor induction vs. 400-800 mcg for abortion). No standard dose reduction is needed; dose is based on gestational age and clinical response.
VYXEOS is a liposomal encapsulation of daunorubicin and cytarabine in a fixed 1:5 molar ratio. It is indicated for adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Do not substitute with other daunorubicin/cytarabine products due to different pharmacokinetics. Monitor for cardiotoxicity (echocardiogram prior to each cycle), myelosuppression, and hepatotoxicity. Premedicate for infusion reactions. Administer as a 90-minute IV infusion on days 1, 3, and 5; no dose adjustment for mild-moderate renal or hepatic impairment but avoid in severe impairment.
Misoprostol is a synthetic prostaglandin E1 analog used off-label for cervical ripening and labor induction, and for medical abortion in combination with mifepristone. It is also used for prevention of NSAID-induced gastric ulcers. For obstetric indications, it can be administered orally, sublingually, vaginally, or buccally, with dosing and route varying by protocol. Onset of action for cervical ripening is 6-8 hours. Contraindicated in pregnancy for ulcer prophylaxis due to abortifacient properties; must be used with caution in women of childbearing age. Common side effects include diarrhea, abdominal pain, and nausea. Misoprostol should not be given simultaneously with magnesium-containing antacids as they may worsen diarrhea.
VYXEOS is a combination chemotherapy used for certain types of acute myeloid leukemia.,It is given as an intravenous infusion over 90 minutes on days 1, 3, and 5 of each treatment cycle.,Common side effects include fever, infection, nausea, vomiting, diarrhea, constipation, mouth sores, fatigue, and bleeding or bruising.,You will have regular blood tests to monitor blood counts, heart function, and liver function.,Report any signs of infection (fever, chills), bleeding (unusual bruising, black stools), shortness of breath, or chest pain immediately.,Avoid pregnancy and breastfeeding while on this medication.,Do not take any other medications, including over-the-counter drugs or supplements, without consulting your doctor.
Take misoprostol exactly as prescribed; do not increase dose or frequency.,For ulcer prevention: take with food and at bedtime, and avoid taking with antacids containing magnesium.,If you are pregnant or could become pregnant, do not use misoprostol for ulcer prevention; it may cause miscarriage or birth defects.,Report severe diarrhea, abdominal pain, or vaginal bleeding to your healthcare provider.,For abortion or labor induction: discuss the full treatment plan and expected symptoms with your doctor.,Do not share this medication with others.
No interactions on record
"The combination of sodium bicarbonate and misoprostol may lead to an increased risk of hypernatremia and fluid overload. Sodium bicarbonate, an alkalinizing agent, can cause sodium retention and volume expansion, while misoprostol, a prostaglandin analog used to prevent NSAID-induced ulcers, can enhance fluid absorption in the gastrointestinal tract, potentially exacerbating electrolyte disturbances and fluid imbalance. This interaction is particularly concerning in patients with compromised renal function or cardiovascular disease."
"Olopatadine, an antihistamine with anticholinergic properties, may diminish the efficacy of misoprostol, a synthetic prostaglandin E1 analog used for cervical ripening and induction of labor. The potential antagonism arises from olopatadine's inhibition of prostaglandin-mediated smooth muscle contraction and mucus secretion. This interaction could lead to reduced misoprostol effectiveness, resulting in inadequate cervical ripening or failure of labor induction."
"Concurrent use of bismuth subcitrate potassium and misoprostol may result in additive gastrointestinal toxicity, including increased risk of diarrhea, abdominal cramping, and potential mucosal irritation. Misoprostol, a prostaglandin E1 analog, stimulates intestinal secretion and motility, while bismuth compounds can cause blackening of the stool and occasional gastrointestinal distress. The combined effect can lead to more pronounced adverse effects without therapeutic benefit, particularly in patients with inflammatory bowel disease or diarrhea-predominant conditions."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VYXEOS vs MISOPROSTOL, answered by our medical review team.
VYXEOS is a Liposomal Antineoplastic Combination that works by Daunorubicin and cytarabine are both antineoplastic agents. Daunorubicin intercalates with DNA, inhibits topoisomerase II, and generates free radicals leading to DNA damage and cell death. Cytarabine is a nucleoside analog that inhibits DNA polymerase by competing with cytidine triphosphate, incorporating into DNA and RNA, and causing chain termination.. MISOPROSTOL is a Prostaglandin Analog that works by Misoprostol is a synthetic prostaglandin E1 analog that induces uterine contractions and cervical ripening by binding to prostaglandin receptors, leading to increased intracellular calcium and myometrial contraction. It also inhibits gastric acid secretion by reducing parietal cell activity and protecting gastric mucosa via increased bicarbonate and mucus production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VYXEOS and MISOPROSTOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VYXEOS is: Each unit contains 44 mg daunorubicin and 100 mg cytarabine. Adults: 1 unit/m² IV over 90 minutes on days 1, 3, and 5 for induction; up to 2 cycles. For consolidation: 1 unit/m² IV over 90 minutes on days 1 and 3; up to 2 cycles.. The standard adult dose of MISOPROSTOL is: 200 mcg orally four times daily (with meals and at bedtime) for prevention of NSAID-induced gastric ulcers; 800 mcg sublingually every 4 hours for up to 3 doses for labor induction; 25 mcg orally single dose for cervical ripening.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VYXEOS and MISOPROSTOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VYXEOS is classified as Category C. VYXEOS (daunorubicin and cytarabine liposome) is contraindicated in pregnancy. It is embryotoxic and fetotoxic in animals. First trimester: high risk of major malformations (neural. MISOPROSTOL is classified as Category D/X. Misoprostol is a prostaglandin E1 analogue that stimulates uterine contractions and causes cervical ripening. It is contraindicated in pregnancy due to its abortifacient properties. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.